Provided by Tiger Fintech (Singapore) Pte. Ltd.

ZAI LAB

17.260
+0.0100.06%
Volume:12.68M
Turnover:217.23M
Market Cap:19.30B
PE:-8.55
High:17.370
Open:17.200
Low:16.940
Close:17.250
52wk High:35.500
52wk Low:16.810
Shares:1.12B
HK Float Shares:1.12B
Volume Ratio:0.65
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-2.019
ROE:-28.97%
ROA:-13.29%
PB:3.27
PE(LYR):-8.55
PS:5.62

Loading ...

HK Stock Connect Shareholding Changes | November 12

Stock News
·
Nov 12

Zai Lab (9688) Announces Grants of Share Options and Restricted Share Units Under Equity Plan

Bulletin Express
·
Nov 11

Zai Lab (09688) Grants Stock Options and Restricted Share Units

Stock News
·
Nov 11

Vertex Reports 64% Proteinuria Reduction With Povetacicept in IgA Nephropathy Trial

Reuters
·
Nov 10

Hong Kong Stock Short Interest Data as of November 7

Stock News
·
Nov 07

Hong Kong Stock Connect Innovative Drug Sector Declines in Afternoon Session, Zai Lab Plunges 10%, 520880 Drops 2% Below 10-Day Moving Average, Intraday Premium Surges

Deep News
·
Nov 07

Zai Lab's Q3 Loss Narrows as Revenue Jumps 14%; Shares Fall 8%

MT Newswires Live
·
Nov 07

Stock Track | Zai Lab Plummets 7.49% as Q3 Earnings Miss Expectations

Stock Track
·
Nov 07

Stock Track | ZAI LAB Plummets 7.49% as Q3 Earnings Miss Estimates, Revenue Falls Short

Stock Track
·
Nov 07

HK Stock Announcement Highlights | GALAXY ENT Q3 Net Revenue Rises 14% YoY to HK$12.2B

Stock News
·
Nov 06

Zai Lab (09688) Reports 14% YoY Revenue Growth in Q3, Totaling $116.1 Million

Stock News
·
Nov 06

Zai Lab Raises 2025 Revenue Guidance to At Least $460 Million

Reuters
·
Nov 06

Zai Lab Ltd: Revising Total Revenue Guidance for Full Year 2025 to at Least $460 Mln

THOMSON REUTERS
·
Nov 06

Zai Lab Says Bemarituzumab Study Stopped for Inadequate Efficacy

MT Newswires Live
·
Nov 05

BRIEF-Zai Lab Updates On Amgen's Bemarituzumab Phase 1B/3 Fortitude-102 Study

Reuters
·
Nov 05

Zai Lab (09688) Provides Update on Amgen's Bemarituzumab Phase 1b/3 FORTITUDE-102 Clinical Trial

Stock News
·
Nov 05

Zai Lab Reports Amgen Halts Phase 1b/3 FORTITUDE-102 Trial for Bemarituzumab in Gastric Cancer

Reuters
·
Nov 05

Zai Lab Ltd - Update on Amgen's Bemarituzumab Phase 1B/3 Fortitude-102 Study

THOMSON REUTERS
·
Nov 05

Zai Lab CFO Yajing Chen Reports Disposal of Common Shares

Reuters
·
Nov 05

Zai Lab Ltd expected to post a loss of 4 cents a share - Earnings Preview

Reuters
·
Nov 04